#LIVE MESSENGER 8 PATCH TRIAL#

Swelling of the face, which may affect people who had facial cosmetic injections in the past, weakness in muscles on one side of the face (acute peripheral facial paralysis or palsy) and hypoaesthesia (reduced sensation to touch, pain and temperature) may affect less than 1 in 1,000 people.ДЄ very small number of cases of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the membrane around the heart) have occurred with Spikevax. Itching at the injection site and dizziness may affect less than 1 in 100 people. Redness, hives and rash at the injection site, sometimes occurring more than a week after injection, and rash may affect less than 1 in 10 people.

They may affect more than 1 in 10 people. The most common side effects are pain and swelling at the injection site, tiredness, chills, fever, swollen or tender lymph nodes under the arm, headache, muscle and joint pain, nausea (feeling sick) and vomiting. The most common side effects with Spikevax in the trials were usually mild or moderate and got better within a few days after vaccination. These results allowed to conclude that the efficacy of Spikevax in children 12 to 17 years old is similar to that in adults.Д¬an people who have already had COVID-19 be vaccinated with Spikevax? In addition, none of 2,163 children receiving the vaccine developed COVID-19, compared with four of 1,073 children given a dummy injection. The study showed that Spikevax produced a comparable antibody response in 12- to 17-year-olds to that seen in young adults (aged 18 to 25 years), as measured by the level of antibodies against SARS-CoV-2. The effects of Spikevax were also investigated in a study involving over 3,000 children aged 12 to 17 years.

#LIVE MESSENGER 8 PATCH TRIAL#

The trial also showed 90.9% efficacy in participants at risk of severe COVID-19, including those with chronic lung disease, heart disease, obesity, liver disease, diabetes or HIV infection. This means that the vaccine demonstrated a 94.1% efficacy in the trial.

The trial showed a 94.1% reduction in the number of symptomatic COVID-19 cases in the people who received the vaccine (11 out of 14,134 vaccinated people got COVID-19 with symptoms) compared with people who received dummy injections (185 out of 14,073 people who received dummy injections got COVID-19 with symptoms).

People did not know whether they received the vaccine or the dummy injections.Д®fficacy was calculated in around 28,000 people from 18 to 94 years of age who had no sign of previous infection. Half received the vaccine and half were given dummy injections. The trial involved around 30,000 people in total. A very large clinical trial showed that Spikevax was effective at preventing COVIDвЂ‘19 in people from 18 years of age.

Live messenger 8 patch